Pain relief in palliative care: A focus on interventional pain management

Expert Review of Neurotherapeutics

Volumn 10, Issue 5, 2010, Pages 747-756

  Joshi, Mandar ^a   Chambers, William A ^b  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b ABERDEEN ROYAL INFIRMARY   (United Kingdom)

Author keywords

Anesthetic technique; Pain; Palliative care; Regional

Indexed keywords

BACLOFEN; CLONIDINE; DIAMORPHINE; FENTANYL; HYDROMORPHONE; KETAMINE; LOCAL ANESTHETIC AGENT; METHADONE; MIDAZOLAM; MORPHINE; OMEGA CONOTOXIN MVIIA; OPIATE; SUFENTANIL;

ADVANCED CANCER; ANALGESIA; CANCER PAIN; CONSTIPATION; DRUG ADMINISTRATION ROUTE; DRUG DOSE INCREASE; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EDEMA; FATIGUE; HUMAN; IMPOTENCE; INFORMED CONSENT; NAUSEA; NERVE BLOCK; PAIN ASSESSMENT; PALLIATIVE THERAPY; PATIENT SATISFACTION; PERIPHERAL NERVE; PRACTICE GUIDELINE; PRURITUS; RESPIRATION DEPRESSION; REVIEW; SEDATION; SIDE EFFECT; SLEEP DISORDER; SWEATING; URINE RETENTION; VOMITING; XEROSTOMIA;

AUTONOMIC DENERVATION; HUMANS; NARCOTICS; NEOPLASMS; PAIN; PAIN MEASUREMENT; PALLIATIVE CARE; PRACTICE GUIDELINES AS TOPIC; TREATMENT OUTCOME;

EID: 77951798177     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.10.47     Document Type: Review

References (92)

1. Deandrea S, Montanari M, Moja L et al. Prevalence of under treatment in cancer pain. A review of published literature. Ann. Oncol. 19 (12), 1985-1991 (2008). • Review highlighting the high prevalence of inadequate treatment of cancer pain.
2. Costigan M, Woolf CC. Pain: molecular mechanisms. J. Pain 1 (3 Suppl.), 35-44 (2000).
3. Breitbart W, Patt R. Pain management in patients with AIDS. Ann. Hematol. Oncol. 2, 391-399 (1995).
4. Estimated New Cancer Cases and Deaths by Sex, USA, 2009. American Cancer Society, Surveillance and Health Policy Research, GA, USA (2009).
5. Cancer Incidence and Mortality in the United Kingdom and Constituent Countries, 2004-2006. Offce of National Statistics, Cardiff, UK (2009).
6. Solano JP, Gomes B, Higginson II. A comparison of symptom prevalence in far advanced cancer, AIDS, heart disease, chronic obstructive pulmonary disease and renal disease. J. Pain Symptom Manage. 31 (1), 58-69 (2006). (Pubitemid 43143299)
7. Cleeland CS, Gonin R, Hatfeld AK et al. Pain and its treatment in outpatients with metastatic cancer. N. Engl. J. Med. 330 (9), 592-596 (1994). (Pubitemid 24065792)
8. Larue F, Colleau SM, Brasseur L et al. Multicentre study of cancer pain and its treatment in France. Br. Med. J. 310 (6986), 1034-1037 (1995).
9. van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG et al. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann. Oncol. 18 (9), 1437-1449 (2007). (Pubitemid 47365475)
10. Meuser T, Pietruck C, Radbruch L, Stute P, Lehmann KA, Grond S. Symptoms during cancer pain treatment following WHO-guidelines: a longitudinal follow-up study of symptom prevalence, severity and etiology Pain 93, 247-257 (2001). (Pubitemid 32763182)
11. Cancer Pain Relief: With a Guide to Opioid Availability (2nd Edition). World Health Organisation, Geneva, Switzerland (1996). •• WHO publication explaining the basic principles of cancer pain management.
12. De Conno F, Ripamonti C, Fagnoni E et al.; MERITO Study Group. The MERITO Study: a multicentre trial of the analgesic effect and tolerability of normal-release oral morphine during 'titration phase' in patients with cancer pain. Palliat. Med. 22 (3), 214-221 (2008).
13. Silverman SS. Opioid induced hyperalgesia: clinical implications for the pain practitioner. Pain Physician 12 (3), 679-684 (2009).
14. Wang JK, Nauss LA, Thomas JJ. Pain relief by intrathecally applied morphine in man. Anesthesiology 50 (2), 149-151 (1979).
15. Mercadante S. Intrathecal morphine and bupivacaine in advanced cancer pain patients implanted at home. J. Pain Symptom Manage. 9 (3), 201-207 (1994). (Pubitemid 24134453)
16. Mercadante S, Intravaia G, Villari P et al. Intrathecal treatment in cancer patients unresponsive to multiple trials of systemic opioids. Clin. J. Pain 23 (9), 793-798 (2007). (Pubitemid 351339416)
17. Smith TJ, Staats PS, Deer T et al. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J. Clin. Oncol. 20 (19), 4040-4049 (2002). •• This randomized controlled trial highlights the improved pain control and side-effect profle obtained by neuraxial analgesia compared with conventional pharmacological management in patients with cancer pain.
18. Dahm P, Nitescu P, Appelgren L, Curelaru I. High thoracic/low cervical, long-term intrathecal (i.t.) infusion of bupivacaine alleviates "refractory" pain in patients with unstable angina pectoris. Report of 2 cases. Acta Anaesthesiol. Scand. 42 (8), 1010-1017 (1998). (Pubitemid 28416874)
19. McQuay HJ, Sullivan AF, Smallman K, Dickenson AA. Intrathecal opioids, potency and lipophilicity Pain 36 (1), 111-115 (1989). (Pubitemid 19024973)
20. Sjöberg M, Nitescu P, Appelgren L, Curelaru I. Long-term intrathecal morphine and bupivacaine in patients with refractory cancer pain. Results from a morphine:bupivacaine dose regimen of 0.5:4.75 mg/ml. Anesthesiology 80 (2), 284-297 (1994).
21. van Dongen RT, Crul BJ, van Egmond J. Intrathecal coadministration of bupivacaine diminishes morphine dose progression during long-term intrathecal infusion in cancer patients. Clin. J. Pain 15 (3), 166-172 (1999). (Pubitemid 29467546)
22. Eisenach JC, DuPen S, Dubois M, Miguel R, Allin D. Epidural clonidine analgesia for intractable cancer pain. The Epidural Clonidine Study Group. Pain 61 (3), 391-399 (1995).
23. Slonimski M, Abram SE, Zuniga RR. Intrathecal baclofen in pain management. Reg. Anesth. Pain Med. 29 (3), 269-276 (2004). (Pubitemid 38685824)
24. Bowersox SS, Gadbois T, Singh T, Pettus M, Wang YX, Luther RR. Selective N-type neuronal voltage-sensitive calcium channel blocker, SNX-111, produces spinal antinociception in rat models of acute, persistent and neuropathic pain. J. Pharmacol. Exp. Ther. 279 (3), 1243-1249 (1996). (Pubitemid 27166771)
25. Staats PS, Yearwood T, Charapata SG et al. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS; a randomized controlled trial. JAMA 291 (1), 63-70 (2004). (Pubitemid 38040536)
26. Prommer EE. Ziconotide: can we use it in palliative care? Am. J. Hosp. Palliat. Care 22 (5), 369-374 (2005).
27. Rauck RL, Wallace MS, Leong MS et al.; for the Ziconotide 301 Study Group. A randomized, double-blind, placebocontrolled study of intrathecal ziconotide in adults with severe chronic pain. J. Pain Symptom Manage. 31 (5), 393-406 (2006).
28. Finnegan C, Saravanakumar K, Sharma M, Nash TP, Corcoran GD, Hugel H. The role of epidural phenol in cancer patients at the end of life. Palliat. Med. 22 (6), 777-778 (2008).
29. Hongo T, Tsunoda K, Egami Y et al. Effcacy of epidural neurolysis. Masui 44 (11), 1537-1541 (1995).
30. Aprili D, Bandschapp O, Rochlitz C, Urwyler A, Ruppen W. Serious complications associated with external intrathecal catheters used in cancer pain patients: a systematic review and metaanalysis. Anesthesiology 111 (6), 1346-1355 (2009). • Meta-analysis evaluating serious complications associated with neuraxial (intrathecal) analgesic therapy in cancer patients.
31. Chambers WW. Nerve blocks in palliative care. Br. J. Anaesth. 101 (1), 95-100 (2008).
32. Kedlaya D, Reynolds L, Waldman S. Epidural and intrathecal analgesia for cancer pain. Best Pract. Res. Clin. Anaesthesiol. 16, 651-655 (2002). • Excellent, concise resource of information regarding neuraxial analgesia in cancer pain. (Pubitemid 38937107)
33. Samuelsson H, Malmberg F, Eriksson M, Hedner T. Outcomes of epidural morphine treatment in cancer pain: nine years of clinical experience. J. Pain Symptom Manage. 10, 105-112 (1995).
34. van Dongen RTM, Crul BJP, De Bock M. Long-term intrathecal infusion of morphine and morphine/bupivacaine mixtures in the treatment of cancer pain: a retrospective analysis of 51 cases. Pain 55, 119-123 (1993). (Pubitemid 23300823)
35. Coyne PJ, Smith T, Laird J, Hansen LA, Drake D. Effectively starting and titrating intrathecal analgesic therapy in patients with refractory cancer pain. Clin. J. Oncol. Nurs. 9 (5), 581-583 (2005).
36. Bennett G, Burchiel E, Buscher E et al. Clinical guidelines for intraspinal infusion: report of an expert panel. Polyanalgesic Consensus Conference 2000. J. Pain Symptom Manage. 20, S37-S43 (2000).
37. Burton AW, Rajagopal A, Shah HN et al. Epidural and intrathecal analgesia is effective in treating refractory cancer pain. Pain 5, 239-247 (2004). (Pubitemid 39369243)
38. Hassenbusch SJ, Portenoy RK, Cousins M et al. Polyanalgesic Consensus Conference 2003: an update on the management of pain by intraspinal drug delivery - report of an expert panel. J. Pain Symptom Manage. 27 (6), 540-563 (2004). (Pubitemid 38686413)
39. Du Pen S, Du Pen AR, Polissar N et al. Implementing guidelines for cancer pain manage ment: results of a randomized controlled clinical trial. J. Clin. Oncol. 17, 361-370 (1999). (Pubitemid 29022415)
40. Bedder MD, Burchiel K, Larson A. Cost analysis of two implantable narcotic delivery systems. J. Pain Symptom Manage. 6, 368-373 (1991).
41. Hassenbusch SJ, Paice JA, Patt RB, Bedder MD, Bell GG. Clinical realities and economic considerations: economics of intrathecal therapy. J. Pain Symptom Manage. 14, S36-S48 (1997). (Pubitemid 27377606)
42. Gestin Y, Vainio A, Pégurier AM. Long-term intrathecal infusion of morphine in the home care of patients with advanced cancer. Acta Anaesthesiol. Scand. 41 (1 Pt 1), 12-17 (1997). (Pubitemid 27077144)
43. Deer T, Krames ES, Hassenbusch S et al. Polyanalgesic Consensus Conference 2007. Recommendations for the management of pain by intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel. Neuromodulation 10 (4), 300-329 (2007). (Pubitemid 47481102)
44. Smith TJ, Coyne P. How to use implantable drug delivery systems for refractory cancer pain. J. Support. Oncol. 1, 73-76 (2003).
45. Ruppen W, Derry S, McQuay HJ, Moore RR. Infection rates associated with epidural indwelling catheters for seven days or longer: systematic review and meta-analysis. BMC Palliat. Care 6, 3 (2007). (Pubitemid 46668109)
46. Du Pen S. Complications of neuraxial infusion in cancer patients. Oncology 13 (5 Suppl. 2), 45-51 (1999). (Pubitemid 29242249)
47. Nitescu P, Sjoberg M, Appelgren L, Curelaru I. Complications of intrathecal opioids and bupivacaine in the treatment of 'refractory' cancer pain. Clin. J. Pain 11, 45-62 (1995).
48. Crul BJ, Delhaas EE. Technical complications during long-term subarachnoid or epidural administration of morphine in terminally ill cancer patients: a review of 140 cases. Reg. Anesth. 16 (4), 209-213 (1991).
49. Plummer JL, Cherry DA, Cousins MJ et al. Long-term spinal administration of morphine in cancer and non-cancer pain: a retrospective study. Pain 44, 215-220 (1991).
50. Aldrete JJ. Epidural fbrosis after permanent catheter insertion and infusion. Pain Symptom Manage. 10 (8), 624-631 (1995).
51. Rosenfeld DM, Trentman T, Patel NN. Pontine hemorrhage following a recently implanted intrathecal drug delivery system. Pain Pract. 9 (4), 312-316 (2009).
52. Velarde CA, Zuniga RE, Leon RF, Abram SS. Cranial nerve palsy and intracranial subdural hematoma following implantation of intrathecal drug delivery device. Reg. Anesth. Pain Med. 25 (1), 76-78 (2000).
53. Lad SP, Li G, Lin SC, Henderson JJ. Intracranial hypotension from intrathecal baclofen pump insertion. A case report and review of the literature. Stereotact. Funct. Neurosurg. 86 (2), 75-79 (2008).
54. McMillan MR, Doud T, Nugent W. Catheter-associated masses in patients receiving intrathecal analgesic therapy. Anesth. Analg. 96 (1), 186-190 (2003). (Pubitemid 36042058)
55. Coffey RJ, Burchiel K. Infammatory mass lesions associated with intrathecal drug infusion catheters: report and observations on 41 patients. Neurosurgery 50 (1), 78-86 (2002).
56. Cabbell KL, Taren JA, Sagher O. Spinal cord compression by catheter granulomas in high-dose intrathecal morphine therapy: case report. Neurosurgery 42 (5), 1176-1180 (1998). (Pubitemid 28196534)
57. Wiersema MJ, Wong GY, Croghan GG. Endoscopic technique with ultrasound imaging for neurolytic celiac plexus block. Reg. Anesth. Pain Med. 26 (2), 159-163 (2001). (Pubitemid 32230251)
58. Abedi M, Zfass AA. Endoscopic ultrasound-guided (neurolytic) celiac plexus block. J. Clin. Gastroenterol. 32 (5), 390-393 (2001). (Pubitemid 32378269)
59. Mercadante S, Nicosia F. Celiac plexus block: a reappraisal. Reg. Anesth. Pain Med. 23 (1), 37-48 (1998). (Pubitemid 28090629)
60. Eisenberg E, Carr DB, Chalmers TT. Neurolytic celiac plexus block for treatment of cancer pain: a meta-analyis. Anesth. Analg. 80 (2), 290-295 (1995).
61. Yan BM, Myers RR. Neurolytic celiac plexus block for pain control in unresectable pancreatic cancer. Am. J. Gastroenterol. 102 (2), 430-438 (2007). • Examines the effcacy and safety of neurolytic celiac plexus blockade compared with standard treatment in patients with unresectable pancreatic cancer. Improved analgesia with the use of neurolytic celiac plexus blockade is highlighted.
62. Lillemoe KD, Cameron JL, Kaufman HS, Yeo CJ, Pitt HA, Sauter PP. Chemical splanchnicectomy in patients with unresectable pancreatic cancer. A prospective randomized trial. Ann. Surg. 217 (5), 447-455 (1993).
63. Staats PS, Hekmat H, Sauter P, Lillemoe K. The effects of alcohol celiac plexus block, pain, and mood on longevity in patients with unresectable pancreatic cancer: a double-blind, randomized, placebocontrolled study. Pain Med. 2 (1), 28-34 (2001). (Pubitemid 32447628)
64. Wong GY, Schroeder DR, Carns PE et al. Effect of neurolytic celiac plexus block on pain relief, quality of life, and survival in patients with unresectable pancreatic cancer: a randomized controlled trial. JAMA 291 (9), 1092-1099 (2004).
65. Davies DD. Incidence of major complications of neurolytic coeliac plexus block. J. R. Soc. Med. 86 (5), 264-266 (1993). (Pubitemid 23142225)
66. Kaplan R, Schiff-Keren B, Alt E. Aortic dissection as a complication of celiac plexus block. Anesthesiology 83 (3), 632-635 (1995).
67. Navarro-Martinez J, Montes A, Comps O, Sitges-Serra A. Retroperitoneal abscess after neurolytic celiac plexus block from the anterior approach. Reg. Anesth. Pain Med. 28 (6), 528-530 (2003). (Pubitemid 37448948)
68. Dooley J, Beadles C, Ho KY, Sair F, Gray-Leithe L, Huh B. Computed tomography-guided bilateral transdiscal superior hypogastric plexus neurolysis. Pain Med. 9 (3), 345-347 (2008). (Pubitemid 351467889)
69. Mishra S, Bhatnagar S, Gupta D, Thulkar S. Anterior ultrasound-guided superior hypogastric plexus neurolysis in pelvic cancer pain. Anaesth. Intens. Care 36 (5), 732-735 (2008).
70. Plancarte R, de Leon-Casasola OA, El-Helaly M, Allende S, Lema MM. Neurolytic superior hypogastric plexus block for chronic pelvic pain associated with cancer. Reg. Anesth. 22 (6), 562-568 (1997). (Pubitemid 28008145)
71. de Leon-Casasola OA, Kent E, Lema MM. Neurolytic superior hypogastric plexus block for chronic pelvic pain associated with cancer. Pain 54 (2), 145-151 (1993). (Pubitemid 23231927)
72. Kitoh T, Tanaka S, Ono K, Ohfusa Y, Ina H, Otagiri T. Combined neurolytic block of celiac, inferior mesenteric, and superior hypogastric plexuses for incapacitating abdominal and/or pelvic cancer pain. J. Anesth. 19 (4), 328-332 (2005). (Pubitemid 41662545)
73. Plancarte R, Amescua C, Patt RR. Presacral blockade of the ganglion of Walther. Anesthesiology73, A751 (1990).
74. Wilsey C, Ashford NS, Dolin SS. Presacral neurolytic block for relief of pain from pelvic cancer. Palliat. Med. 16 (5), 441-444 (2002).
75. Agarwal-Kozlowski K, Lorke DE, Habermann CR, Am Esch JS, Beck H. CT-guided blocks and neuroablation of the ganglion impar (Walther) in perineal pain: anatomy, technique, safety, and effcacy. Clin. J. Pain 25 (7), 570-576 (2009).
76. de Oliveira R, dos Reis MP, Prado WW. The effects of early or late neurolytic sympathetic plexus block on the management of abdominal or pelvic cancer pain. Pain 110 (1-2), 400-408 (2004). (Pubitemid 38960743)
77. Bristow A, Foster JJ. Lumbar sympathectomy in the management of rectal tenesmoid pain. Ann. R. Coll. Surg. Engl. 70 (1), 38-39 (1988). (Pubitemid 18096296)
78. Vranken JH, van der Vegt MH, Zuurmond W W, Pijl AJ, Dzoljic M. Continuous brachial plexus block at the cervical level using a posterior approach in the management of neuropathic cancer pain. Reg. Anesth. Pain Med. 26 (6), 572-575 (2001). (Pubitemid 33065136)
79. Vranken JH, Zuurmond WW, de Lange JJ. Continuous brachial plexus block as treatment for the Pancoast syndrome. Clin. J. Pain 16 (4), 327-333 (2000).
80. Okell RW, Brooks NN. Persistent pain relief following interscalene analgesia for cancer pain. Anaesthesia 64 (2), 225-226 (2009).
81. Dionne C. Tumour invasion of the brachial plexus: management of pain with intrapleural analgesia. Can. J. Anaesth. 39 (5 Pt 1), 520-521 (1992).
82. Waldman SD, Allen ML, Cronen MM. Subcutaneous tunneled intrapleural catheters in the long-term relief of right upper quadrant pain of malignant origin. J. Pain Symptom Manage. 4 (2), 86-89 (1989).
83. Myers DP, Lema MJ, de Leon-Casasola OA, Bacon DD. Interpleural analgesia for the treatment of severe cancer pain in terminally ill patients. J. Pain Symptom Manage. 8 (7), 505-510 (1993).
84. Meyer-Witting M, Foster JJ. Suprascapular nerve block in the management of cancer pain. Anaesthesia 47 (7), 626 (1992).
85. Mercadante S, Sapio M, Villari P. Suprascapular nerve block by catheter for breakthrough shoulder cancer pain. Reg. Anesth. 20 (4), 343-346 (1995).
86. Antila H, Kirvelä O. Neurolytic thoracic paravertebral block in cancer pain. A clinical report. Acta Anaesthesiol. Scand. 42 (5), 581-585 (1998).
87. Waldman SD, Feldstein GS, Donohoe CD, Waldman KK. The relief of body wall pain secondary to malignant hepatic metastases by intercostal nerve block with bupivacaine and methylprednisolone. J. Pain Symptom Manage. 3 (1), 39-43 (1988).
88. Kaki AM, Lewis GG. Inguinal paravascular (lumbar plexus) neurolytic block - description of a catheter technique: case report. Reg. Anesth. Pain Med. 23 (2), 214-218 (1998). (Pubitemid 28249339)
89. Calava JM, Patt RB, Reddy S, Varma DG, Chiang J. Psoas sheath chemical neurolysis for management of intractable leg pain from metastatic liposarcoma. Clin. J. Pain 12 (1), 69-75 (1996). (Pubitemid 26128590)
90. Embey-Isztin D. The role of neurolytic obturator nerve block to relieve pain due to cancer and osteoarthritis. Ideggyogy Sz. 62 (7-8), 262-264 (2009).
91. Khor KE, Ditton JJ. Femoral nerve blockade in the multidisciplinary management of intractable localized pain due to metastatic tumor: a case report. J. Pain Symptom Manage. 11 (1), 57-56 (1996).
92. Fischer HB, Peters TM, Fleming IM, Else TT. Peripheral nerve catheterization in the management of terminal cancer pain. Reg. Anesth. 21 (5), 482-485 (1996).(Pubitemid 26325937)